Clinical Trial Update: A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating autogene cevumeran plus atezolizumab with mFOLFIRINOX versus mFOLFIRINOX in patients with resected pancreatic ductal adenocarcinoma; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Autogene Cevumeran (autogene cevumeran)
• mFOLFIRINOX

Snippet

Sponsor: Genentech, Inc. | Conditions: Adenocarcinoma, Pancreatic Ductal | Phase 2 | Status: RECRUITING